Back to Studies

Study analysis · Journal of Human Nutrition and Dietetics · 2026

You can get stronger after cancer surgery—even as your muscles shrink.

After cancer surgery, people lose muscle but get stronger and walk faster, meaning strength doesn't always mean you have more muscle.

Reading level
Low certainty
Level 2b · Individual cohort studyAssociation, not causationNo causal claims

Overview

What the study found

The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.

In simple terms

This study watched a group of cancer patients before and after surgery to see how their muscles changed. It found that their muscles got smaller, but their strength got better — but it didn't test why. So we can say these things happened together, but we can't say one caused the other.

What’s the bottom line?

After cancer surgery, many patients lose muscle bulk, but their strength and ability to walk often get better — even though their muscles are still smaller.

How strong is this study?

The researchers measured muscle carefully and checked it many times, which is good. But they only studied 48 people, and many dropped out, so we can't be sure the results apply to everyone. Also, they didn't compare these patients to others who didn't have surgery, so we don't know if the changes were really because of the surgery.

Reporting

40 / 100

  • COI disclosure+40/40
  • Data availabilitydata not shared
  • Code availabilitycode not shared
Methodology

18 / 100

  • Randomizationnot randomized
  • Blindingblinding unclear
  • Control groupno control group
  • Sample size (n=48)+4.3/20
  • Follow-up+10/10
Publication

100 / 100

Statistical

77 / 100

  • P-values+15/15
  • Effect size+20/20
  • Confidence intervals+15/15
  • Pre-registrationnot pre-registered

Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.

Where it sits

RCT reviews

Max 100

Randomized Trials

Max 90

Reviews of Cohort Studies

Max 85

Cohort Studies

Max 72

Reviews of Case-Control Studies

Max 63

Case-Control Studies

Max 58

Cross-Sectional & Case Series

Max 50

Expert Opinion

Max 5
StrongerWeaker
Cohort Studies
Level 2b
53

53 / 100

Probability of being correct

Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.

This design cannot establish causation — the findings describe an association, not a cause. This is an observational cohort study without randomization or control group; it can identify associations over time but cannot rule out confounding factors such as neoadjuvant therapy, diet, or pre-existing conditions that may influence muscle changes.

No Conflicts

No conflicts of interest identified

No conflicts of interest or funding disclosures were reported in the study text. All methods and analyses appear independently conducted without industry influence.

Independent Analysis Safeguards

  • CT images were analyzed by two trained assessors blinded to patient outcomes
  • Inter- and intra-rater coefficient of variation was reported (mean 0.73%)
  • BIS measurements followed standardized protocols with quality control checks
  • Statistical analysis used mixed-effects models with random effects per patient to account for longitudinal data

The study lacks a formal conflict of interest statement or funding disclosure section, which is a limitation in transparency. However, no industry ties, author affiliations with commercial entities, or funder involvement were identified in the provided text. The methodology includes robust independent analysis safeguards.

Key takeaways

  1. 01

    50% had low muscle mass before surgery; only 15% had full sarcopenia (low mass + low strength + slow walking).

  2. 02

    After surgery, muscle kept shrinking, but grip strength and walking speed got better than before surgery.

  3. 03

    Yes — even if you look stronger and walk better after surgery, you might still have dangerously low muscle mass, which can affect survival.

Surprising findings

  • Muscle mass declined significantly after surgery and never recovered, yet hand grip strength and walking speed improved beyond preoperative levels by 12 months.Common belief: if you lose muscle, you get weaker. This study shows the opposite—patients got stronger and faster even as their muscles shrank, suggesting functional adaptation independent of muscle size.
  • Sarcopenia prevalence dropped from 15% to 12% by CT over 12 months, despite persistent muscle loss.You’d expect sarcopenia to get worse as muscle declines—but it didn’t, because strength and function improved, masking the true muscle deficit.

Practical takeaways

If you or a loved one is recovering from cancer surgery, ask for a CT-based muscle mass assessment—not just grip strength or body weight.

CT scans involve radiation and aren’t always accessible; BIS is easier but unreliable. Ask your care team if they can track muscle mass via imaging.

medium confidence

Don’t assume improved strength or walking speed means muscle has recovered—persistent low muscle mass is linked to worse survival.

Improvements in function are still positive and should be encouraged, but they shouldn’t replace muscle mass monitoring.

high confidence

If using a BIS scale at home, understand it may not detect muscle loss in cancer patients—use it for trends, not diagnosis.

BIS accuracy is compromised by fluid shifts common after surgery or during chemo.

medium confidence

Why this study matters

Muscle Loss Without Strength Loss

50% of patients had low skeletal muscle index (SMI) before surgery, yet only 15% met the full sarcopenia diagnosis (low mass + low strength + low function). After surgery, muscle mass kept declining (SMI dropped from 47.2 to 45.1 cm²/m²), but hand grip strength and gait speed improved and exceeded preoperative levels by 12 months.

This flips the script: you can look weaker on a scan but feel stronger in real life. It means your body can adapt functionally even when muscle tissue is disappearing—something most people assume doesn’t happen.

BIS vs CT: The Tool That Lies

Bioimpedance spectroscopy (BIS) detected only 2% of patients with sarcopenia pre-surgery, while CT scans found 15%—a 7.5x difference. BIS underestimated muscle loss because it can’t distinguish between muscle and fluid, especially in post-op patients.

Many at-home body fat scales use BIS. This study shows they could be missing dangerous muscle loss in cancer patients—potentially delaying life-saving interventions.

Strength Isn’t a Proxy for Muscle

35% of patients with low muscle mass by CT had normal hand grip strength. Muscle quantity and strength are independently variable—meaning you can have weak muscles without weak hands, and vice versa.

Doctors often use grip strength as a quick screen for muscle health. This study proves it’s unreliable in cancer patients—leading to false reassurance and missed diagnoses.

Want the whole report?

Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.